Article
A new kind of drug, a Raf kinase inhibitor, is well-tolerated and may prove effective in treating patients with metastatic melanoma, according to researchers from the Abramson Cancer Center of the University of Pennsylvania.
Closing the Wound Care Gap: Addressing Disparities in Amputations and Limb Preservation
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Botox Cosmetic: Ethics, Empowerment, and Innovation
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Information on TikTok About Spironolactone is Unreliable, New Study Finds
Vitiligo, Melasma, PIH, and Albinism: Clinical Update and Emerging Therapies